公开(公告)号：CA3022256C

公开(公告)日：2021-03-30

申请号：CA3022256

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K9/48 ,  A61K39/395 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ717373A

公开(公告)日：2017-11-24

申请号：NZ71737311

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK D ,  FYFE GWEN ,  BUGGY JOSEPH J

IPC: A61K31/4162 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765), in the manufacture of a medicament for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has already received at least one prior therapy for MZL.

公开(公告)号：CA3154024A1

公开(公告)日：2011-12-08

申请号：CA3154024

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are uses of a compound (ibrutinib) for treating follicular lymphoma, wherein the compound has the structure:

公开(公告)号：AU2020202752A1

公开(公告)日：2020-05-14

申请号：AU2020202752

申请日：2020-04-24

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3007787C

公开(公告)日：2020-03-10

申请号：CA3007787

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ736048A

公开(公告)日：2019-09-27

申请号：NZ73604811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Described is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating relapsed or refractory follicular lymphoma in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：AU2015275321B2

公开(公告)日：2018-03-15

申请号：AU2015275321

申请日：2015-12-23

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. (1 Rd7fl1 11-MCH

公开(公告)号：PH12016501206B1

公开(公告)日：2018-02-12

申请号：PH12016501206

申请日：2016-06-20

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/505 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：PH12016501206A1

公开(公告)日：2018-02-12

申请号：PH12016501206

申请日：2016-06-20

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/505 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3113343A1

公开(公告)日：2011-12-08

申请号：CA3113343

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.